AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26176605
Drug: Selective low-dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Selective low-dose spinal anesthesia
Trial: 19168521
Drug: Continuous aortic
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous aortic flow augmentation device
Trial: 19168521
Drug: Thyroid hormone
RxNorm normalized name: Thyroid hormone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid hormone analogue
Trial: 15326018
Drug: Survey of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Survey of internal medicine residents
Trial: 11430963
Drug: Raloxifene 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene 120 mg per day
Trial: 3623678
Drug: Nifedipine, 20
RxNorm normalized name: Nifedipine, 20 mg oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine, 20 mg p.o.
Trial: 25527456
Drug: Single 2-L
RxNorm normalized name: Iron(2+) L-ascorbate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single 2-L dose of Moviprep
Trial: 25527456
Drug: Two separate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two separate doses of 1 L of Moviprep
Trial: 21855837
Drug: Prolonged bivalirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged bivalirudin infusion (4-hour infusion after PCI)
Trial: 21855837
Drug: Standard bivalirudin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard bivalirudin infusion (peri-PCI infusion)
Trial: 22162175
Drug: Heparin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin plus abciximab
Trial: 19247742
Drug: Group A
RxNorm normalized name: Blood group A IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group A (10 ml 0.5% - 50 mg)
Trial: 19247742
Drug: Group B
RxNorm normalized name: Blood group B IgM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group B (10 ml 0.25% - 25 mg)
Trial: 19247742
Drug: Group C
RxNorm normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group C (40 ml 0.0625% - 25 mg)
Trial: 15229391
Drug: High-dose bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bolus tirofiban (n = 50)
Trial: 3377459
Drug: Carumonam (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carumonam (1 g every 8 h)
Trial: 3377459
Drug: Gentamicin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin (1 mg/kg every 8 h)
Trial: 19117887
Drug: Laronidase (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laronidase (recombinant human alpha-l-iduronidase)
Trial: 16937109
Drug: Profylin fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Profylin fluoride gel with buffering components (active gel)
Trial: 16937109
Drug: Profylin fluoride
RxNorm normalized name: Hydrogen fluoride
DrugBank: Hydrogen fluoride (DB11072)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Profylin fluoride gel without buffering components (placebo gel)
Trial: 9118789
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg ofloxacin and 500 mg metronidazole intravenously, twice daily
Trial: 9118789
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no initial antibiotics), n = 13
Trial: 8335858
Drug: Regular use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular use of Beconase AQ nasal spray (400 micrograms daily)
Trial: 8335858
Drug: As required
RxNorm normalized name: rabies vaccine, for intramuscular injection RETIRED CODE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As required (prn) use of Beconase AQ nasal spray
Trial: 19070383
Drug: ARB (losartan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ARB (losartan 25‐50mg/day, candesartan 4‐8 mg/day, valsartan 40‐80 mg/day, telmisartan 20‐40 mg/day)
Trial: 14757258
Drug: Antiarrhythmic Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic Therapy
Trial: 2129071
Drug: High-dose glycyrrhizin
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose glycyrrhizin (Stronger Neo-Minophagen C, SNMC) administered intravenously daily for the first 3 weeks, and every second day for the following 8 weeks. Dosage: 100-200 ml in 21 patients and 400-800 ml in the other 21.
Trial: 7380749
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention and methylphenidate (0.25 mg/kg)
Trial: 7380749
Drug: Behavioral intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Behavioral intervention and methylphenidate (0.75 mg/kg)
Trial: 7380749
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of methylphenidate after 13 weeks of behavioral intervention
Trial: 7380749
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of methylphenidate after 13 weeks of behavioral intervention
Trial: 7380749
Drug: No medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No medication after 13 weeks of behavioral intervention
Trial: 31410968
Drug: 1-month dual
RxNorm normalized name: miconazole
DrugBank: Miconazole (DB01110)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1-month dual antiplatelet therapy (DAPT) with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy
Trial: 31854112
Drug: Standard 12-month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard 12-month DAPT followed by 12-month aspirin monotherapy
Trial: 31410968
Drug: 1-month DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1-month DAPT with ticagrelor and aspirin followed by 23-month ticagrelor monotherapy
Trial: 25081735
Drug: Isotretinoin with
RxNorm normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isotretinoin with additional antihistamine (desloratadine)
Trial: 2479083
Drug: Self-administration of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self-administration of pancreatic enzyme substitution (Pancrease)
Trial: 2479083
Drug: Regular dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dosage of pancreatic enzyme substitution (Pancrease)
Trial: 1096685
Drug: combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: combination of naphazoline hydrochloride and antazoline phosphate
Trial: 31536941
Drug: Non-severe hypoglycaemic
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-severe hypoglycaemic clamp (plasma glucose: 3.1 ± 0.3 mmol/L)
Trial: 31536941
Drug: Normoglycaemic clamp
RxNorm normalized name: CLAMP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normoglycaemic clamp (plasma glucose: 5.8 ± 0.3 mmol/L)
Trial: 26403986
Drug: Oral arsenic
RxNorm normalized name: arsenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral arsenic (Realgar‐Indigo naturalis formula, RIF) plus all‐trans retinoic acid (ATRA)
Trial: 26403986
Drug: Oral arsenic
RxNorm normalized name: arsenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral arsenic (RIF) during maintenance treatment
Trial: 26403986
Drug: Intravenous arsenic
RxNorm normalized name: arsenic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous arsenic trioxide (ATO) during maintenance treatment
Trial: 23999661
Drug: 1.1 g
RxNorm normalized name: Giazo 1.1 GM Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1 g of n‐3 PUFA daily for six weeks
Trial: 23999661
Drug: 2 g
RxNorm normalized name: Molds 2 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 g of olive oil daily for six weeks
Trial: 18998188
Drug: Phytosterol-enriched yogurt
RxNorm normalized name: phytosterols
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phytosterol-enriched yogurt (1.6 g esterified phytosterols, equivalent to 1.0 g free phytosterol)
Trial: 16452747
Drug: Weekly dry
RxNorm normalized name: elagolix
DrugBank: Elagolix (DB11979)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly dry dressing changes without pin-site care
Trial: 16452747
Drug: Daily pin-site
RxNorm normalized name: pin oak pollen extract
DrugBank: Quercus palustris pollen (DB10887)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily pin-site care with a solution of one-half normal saline solution and one-half hydrogen peroxide
Trial: 16452747
Drug: Chlorhexidine-impregnated discs
RxNorm normalized name: DISC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorhexidine-impregnated discs (Biopatch) with weekly changes
Trial: 8929232
Drug: Bunazosin retard
RxNorm normalized name: bunazosin
DrugBank: Bunazosin (DB12230)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bunazosin retard (6 mg)
Trial: 17304143
Drug: Azathioprine (2.0-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2.0-2.5 mg/kg per day)
Trial: 8878220
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin A therapy
Trial: 6366346
Drug: 1% aqueous
RxNorm normalized name: Zotane-HC 0.1%-1%-1% Aqueous Otic Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% aqueous solution of indomethacin
Trial: 17599420
Drug: Fibrate and
RxNorm normalized name: Fenofibrate and rosuvastatin only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrate and statin therapy for lipid management
Trial: 15691617
Drug: Spironolactone 50
RxNorm normalized name: spironolactone 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Spironolactone 50 mg for 4 weeks
Trial: 15691617
Drug: Bendroflumetazide 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bendroflumetazide 2.5 mg for 4 weeks
Trial: 9794277
Drug: Cognitive therapy
RxNorm normalized name: cognitive therapy software
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive therapy (CT) - 12 weekly sessions of individual CT
Trial: 8560527
Drug: Dextrose 2
RxNorm normalized name: Dextrose 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 2 mg/kg/min infused over 60 min with heparin and Intralipid (group C)
Trial: 8560527
Drug: Dextrose 2
RxNorm normalized name: Dextrose 2.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 2 mg/kg/min infused over 60 min alone (group A)
Trial: 8560527
Drug: Dextrose 4
RxNorm normalized name: DEXTROSE 40% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 4 mg/kg/min alone (group B)
Trial: 8560527
Drug: Dextrose 4
RxNorm normalized name: DEXTROSE 40% INJ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextrose 4 mg/kg/min with heparin and Intralipid (group D)
Trial: 2155688
Drug: Nedocromil sodium
RxNorm normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nedocromil sodium (2.6 mg active drug per nostril, q.i.d.)
Trial: 25308868
Drug: Amitriptyline hydrochloride
RxNorm normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline hydrochloride 10 mg
Trial: 25308868
Drug: Amitriptyline hydrochloride
RxNorm normalized name: Amitriptyline Hydrochloride
DrugBank: Amitriptyline (DB00321)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amitriptyline hydrochloride 25 mg
Trial: 23570280
Drug: Compounded morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compounded morphine
Trial: 19351732
Drug: Oral estradiol
RxNorm normalized name: estradiol Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral estradiol and progesterone for 7 days
Trial: 11522495
Drug: HDV-insulin (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HDV-insulin (0.1 U/kg)
Trial: 11522495
Drug: Regular insulin
RxNorm normalized name: Regular insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular insulin (0.1 U/kg)
Trial: 11522495
Drug: HDV-insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HDV-insulin
Trial: 3302342
Drug: Ampicillin suppository
RxNorm normalized name: Ampicillin
DrugBank: Ampicillin (DB00415)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ampicillin suppository (4 x 125 mg)
Trial: 3302342
Drug: Oral form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral form of ampicillin (4 x 125 mg)
Trial: 22957521
Drug: Tight glycemic
RxNorm normalized name: Glycerin
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tight glycemic control (insulin-dosing algorithm targeting blood glucose level of 80 to 110 mg/dL)
Trial: 17666497
Drug: Long-acting risperidone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-acting risperidone (25 mg or 50 mg every 14 days)
Trial: 17666497
Drug: Oral olanzapine
RxNorm normalized name: Olanzapine
DrugBank: Olanzapine (DB00334)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral olanzapine (5-20 mg/day)
Trial: 15502112
Drug: Budesonide/formoterol (bud/form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (bud/form) maintenance + relief (80/4.5 microg twice a day with 80/4.5 microg as-needed)
Trial: 15502112
Drug: Budesonide/formoterol (bud/form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide/formoterol (bud/form) + SABA (terbutaline 0.4 mg)
Trial: 15502112
Drug: Budesonide (bud)
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide (bud) + SABA (terbutaline 0.4 mg)
Trial: 9585655
Drug: Amitriptyline (AMI),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline (AMI), flexible dose, final dose 173.1 mg/day ± 56.3 mg/day
Trial: 779502
Drug: Clofazimine 200
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofazimine 200 mg daily 6 days per week (regimen 1)
Trial: 779502
Drug: Clofazimine 100
RxNorm normalized name: clofazimine 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clofazimine 100 mg three times weekly (regimen 2)
Trial: 779502
Drug: Clofazimine 300
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofazimine 300 mg weekly (regimen 3)
Trial: 779502
Drug: Clofazimine 600
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofazimine 600 mg every other week (regimen 4)
Trial: 779502
Drug: Clofazimine 600
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofazimine 600 mg on 2 consecutive days every 4 weeks (regimen 5)
Trial: 779502
Drug: Clofazimine 200
RxNorm normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clofazimine 200 mg daily 6 days per week (regimen 6)
Trial: 779502
Drug: Dapsone, starting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapsone, starting with a small dosage and increasing to 100 mg daily 6 days per week (regimen 7)
Trial: 29744804
Drug: Controlled antipsychotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled antipsychotic treatment for 12 weeks
Trial: 30376810
Drug: Programmed Intermittent
RxNorm normalized name: Program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Programmed Intermittent Epidural Bolus (PIEB) 6 mL/h of ropivacaine 0.2%
Trial: 30376810
Drug: Continuous Epidural
RxNorm normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Epidural Infusion (CEI) 6 mL/h of ropivacaine 0.2%
Trial: 26772985
Drug: Early prophylactic
RxNorm normalized name: polylactic acid-polyglycolic acid copolymer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early prophylactic levothyroxine (LT4) treatment
Trial: 22095403
Drug: Manual (non-US-guided)
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual (non-US-guided) injection
Trial: 22095403
Drug: Comparison of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparison of US-guided vs Manual injection
Trial: 16252739
Drug: Injection pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection pressure of 30 s/mL
Trial: 16252739
Drug: Injection pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection pressure of 160 s/mL
Trial: 12014163
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no solution applied)
Trial: 31769596
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (non-animal stabilized) (DB19175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hyaluronic acid gel treatment
Trial: 31134827
Drug: Hyperbaric oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric oxygen therapy (HBO) in addition to conventional treatment, 5 days per week, 60 min each, 100% oxygen at 2 standard atmospheric pressures for 12 weeks.
Trial: 31134827
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (Control group).
Trial: 28186838
Drug: Group <70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group <70 (mean dose <70.2Gy)
Trial: 28186838
Drug: Group >70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group >70 (mean dose >70.2Gy)
Trial: 26404912
Drug: Tiotropium 1.25
RxNorm normalized name: TIOTROPIUM 1.25MCG/ACTUAT 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 1.25 µg + Olodaterol 5 µg
Trial: 26404912
Drug: Tiotropium 2.5
RxNorm normalized name: TIOTROPIUM 2.5MCG/ACTUAT 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 2.5 µg + Olodaterol 5 µg
Trial: 26404912
Drug: Tiotropium 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 5 µg + Olodaterol 5 µg
Trial: 26404912
Drug: Tiotropium 1.25
RxNorm normalized name: TIOTROPIUM 1.25MCG/ACTUAT 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 1.25 µg + Olodaterol 10 µg
Trial: 26404912
Drug: Tiotropium 2.5
RxNorm normalized name: TIOTROPIUM 2.5MCG/ACTUAT 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 2.5 µg + Olodaterol 10 µg
Trial: 26404912
Drug: Tiotropium 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiotropium 5 µg + Olodaterol 10 µg
Trial: 21495198
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg of hyoscine-N-butyl bromide (HBB) rectal suppository
Trial: 19054777
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone application preceding standard gonadotrophin ovarian stimulation
Trial: 19054777
Drug: High-dose gonadotrophin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose gonadotrophin with minidose GnRH agonist protocol
Trial: 19054777
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone application
Trial: 19054777
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone application (normal basal FSH levels)
Trial: 19054777
Drug: High-dose gonadotrophin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose gonadotrophin with minidose GnRH agonist protocol (normal basal FSH levels)
Trial: 17613264
Drug: NO-collecting solutions
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NO-collecting solutions with NO-scavenging compounds (hemoglobin or 2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl 3-oxide) placed inside tubing attached to skin for 20 min
Trial: 15598977
Drug: IM862 (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM862 (5 mg intranasally every other day)
Trial: 9617985
Drug: Naltrexone 200
RxNorm normalized name: NALTREXONE 200 mg / TRIAMCINOLONE 6.5 mg SUBCUTANEOUS IMPLANT [Naltrexone]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 200 mg/day for 3 weeks
Trial: 9617985
Drug: Naltrexone (subsequent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone (subsequent treatment)
Trial: 7925218
Drug: Rocuronium 0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rocuronium 0.6 mg kg‐1 for intubation followed by an infusion controlled by closed‐loop feedback at 90% block.
Trial: 2701811
Drug: Inappropriate sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inappropriate sequential analysis
Trial: 772669
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of pseudoephedrine and triprolidine
Trial: 31229641
Drug: r-ATG (4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-ATG (4.5 mg/kg)
Trial: 28965280
Drug: Acetazolamide (oral,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetazolamide (oral, once daily, dose-adjusted to body weight)
Trial: 19565156
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy agents + isometric and stretching exercises
Trial: 19565156
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy agents
Trial: 14666399
Drug: Paroxetine (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paroxetine (40 mg daily)
Trial: 9209013
Drug: Beta-carotene and
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene and other compounds